Introduction
Lung cancer is one of the most common malignancies as well as the leading cause of cancer-related death both in males and females worldwide. 1 Non-small-cell lung cancer (NSCLC) constitutes for about 80% of all lung cancer cases. About 55% ofby International Association for the Study of Lung Cancer International Staging Project is widely accepted as a tool to predict the prognosis of patients and had been updated to the eighth edition. The eighth TNM stage took the number of metastatic sites into consideration and divided the cases with distant metastasis into M1b (single metastatic site) and M1c (multiple metastatic sites) subgroups. However, different metastatic organs are associated with different prognosis, and it ignores patients' physical condition, 7, 9 pathological or genotype characteristics, and treatments. Therefore, it is still difficult to predict individual prognosis of metastatic lung cancer precisely and accurately by this tool.
Nomogram is a commonly feasible tool to predict disease prognostication of patients. 9 In recent decades, several nomograms have been developed for metastatic NSCLC patients with brain metastasis, 10 or treated with chemotherapy, 3, 6 but no nomogram is constructed for the general distantly metastatic NSCLC cohort. In addition, EGFR-tyrosine kinase inhibitors (EGFR-TKIs) have been widely used since 2010, 11 which would change the prognosis of distantly metastatic NSCLC. Therefore, the present study aimed to develop and validate a novel nomogram for this cohort by examining the cases diagnosed between 2010 and 2014 from the Surveillance, Epidemiology, and End Results (SEER) database, which covers 34.6% of the US population.
12
Patients and methods study population and data processing 13 We defined a new item "With M1a". If the CS Mets at dx code of a patient was coded as one of them, his/her "With M1a" item would be coded as "Yes". Age is a continuous variable and was transformed into categorical variables according to the cutoff values determined by the X-tile software (https://medicine.yale.edu/lab/rimm/ research/software.aspx). The software can divide continuous variable into several subgroups with the largest chi-squared log-rank value and the minimum P-value rationally.
14 Surgery of primary cancer and radiation therapy was divided into two categories ("yes" or "no"). Overall survival (OS) was defined as the time from diagnosis to death despite the causes.
statistical analysis
The cases that we finally included were assigned randomly into the training and validation sets in a 4:1 ratio by the digital method. We performed a descriptive analysis of 
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a nomogram predicting the Os of patients with distantly metastatic nsClC the demographic and clinicopathological features of the included patients in training and validation sets. At the same time, we calculated the median survival time (95% CI) for each subgroup using the Kaplan-Meier analysis. In the training cohort, prognostic risks of the OS were identified using the unadjusted univariable Cox regression analysis. Variables that reached statistical significance (P<0.05) were involved into multivariable analyses. According to the results of the Cox proportional hazards model, variables that remained statistically significance (P<0.05) were incorporated to construct the nomogram by R software version 3.3.3 (Institute for Statistics and Mathematics, Vienna, Austria; www.r-project.org) with the "rms" and "survival" package. The nomogram adopted the 1-and 2-year OS as the endpoints. We used the Harrell's concordance index (C-index) with a 95% CI to evaluate the discriminative ability of the nomogram by 1,000 bootstraps resamples for internal validation in the training cohort and external validation in the validation set, respectively. We developed calibration blots in the two sets to visualize the agreement between the predicted and observed 1-and 2-year OS to assess the predicted accuracy of the nomogram. In addition, patients in the validation set were assigned into different risk groups according to quartile of prognostic scores in training cohort. Survival curves for different risk groups in the validation set were generated by the Kaplan-Meier analysis and compared using the log-rank test in order to investigate the discriminate ability of the nomogram. Two-sided P-values <0.05 were considered as statistically significance. All statistical analysis procedures were performed using SPSS 23.0 (SPSS Inc., Chicago, IL, USA).
Results

Baseline clinicopathological features
Finally, a total of 18,209 cases that met our criteria were extracted from the SEER database. The details of caseselection procedures are demonstrated in Figure 1 . The entire cohort was randomly allocated into two groups, 14,567 cases in the training cohort and 3,642 cases in the validation cohort, respectively. The demographic and clinicopathological features of the patients in the two cohorts are shown in Table 1 (Table S1 ). These prognostic factors were then included in the multivariable analysis, and we observed that radiation therapy was not significantly associated with the OS (P=0.143) (Table S1 ). During the analysis process, we found that some subgroups of patients had similar OS, we thereby combined these subgroups as one category in the multivariable analysis, including White and Black populations, T2, T3, T4, and Tx, grade I and grade II, as well as grade III and grade X, N1, N2, N3, and Nx. After combining these subgroups, we conducted the multivariable analysis again. The results showed that all of these factors were still significantly associated with OS. All factors were then incorporated to develop the nomogram. However, we found that four subgroups of tumor sites scored 0, therefore, these variables were removed from the following analysis.
After that, we performed the multivariable analysis again, and the remaining 14 variables remained the prognostic factors of OS (Table 2) .
nomogram development and validation
We then constructed a nomogram integrating these prognostic factors using the training cohort ( Figure 2 ). As is shown in the nomogram, chemotherapy made the largest contribution to the prognosis, followed by surgery of primary cancer, interestingly. Race, tumor grade, presence of liver, bone metastasis, age, T stage, N stage, and histology, which showed moderate impacts on the OS, while the presence of M1a disease, brain metastasis, sex, and marital status made the modest difference to the prognosis. Each negative subtype within these variables was assigned a score (Table 3) . By adding up these scores according to a patient's condition, the total score was obtained. Then, the total score was located on the total point line, and a straight line could be drawn to estimate the patient's probability of 1-and 2-year OS. The nomogram had a C-index of 0.704 (95% CI: 0.699-0.709) in the training set and 0.699 (95% CI: 0.689-0.709) in the validation set. The calibration curves for 1-and 2-year OS 
6148
Deng et al showed acceptable agreement between the predicted and actual survival in both cohorts (Figures 3 and 4) .
Risk stratifications
We added the total score for every patient in the training set, and then sorted the patients according to the scores to get the quartile of prognosis scores: Min-224, 225-259, 260-311, and 312-Max. Each risk group represented a distinct prognosis. We observed significant distinctions between the Kaplan-Meier curves (P=0.00) within overall patients or patients with brain, liver, bone metastasis, as well as T0, T1 stage, T2-4, Tx stage, N0 stage, and N1-3, Nx stage, 
Discussion
In the current study, we established a nomogram to predict the prognosis of general distantly metastatic NSCLC patients using the data retrieved from the SEER database. A total of 18,209 cases were included, and 14 significant prognosis factors that represent demographic, pathological, and treatment data were identified by conducting uni-and subsequent multivariable analysis in the training set and then integrated to construct the nomogram. The validation showed that the nomogram is of acceptable discrimination ability with a C-index of 0.704 (95% CI: 0.699-0.709) in the training set and 0.699 (95% CI: 0.689-0.709) in the validation set. As is shown in the calibration blots, the nomogram can predict 
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Deng et al 1-and 2-year OS accurately. The nomogram was also capable of stratifying patients into different risk groups within the patients presented with bone, liver, or brain metastasis, as well as T, N stages. To the best of our knowledge, this is the first prognosis nomogram developed for general NSCLC patients with distant organ metastasis based on a large, diverse, population-based cohort that was collected from the SEER program. This nomogram can easily predict the prognosis of a patient and inform individual benefits of certain medical treatments as well as stratify the patient into different risk subgroups, which might be meaningful and informatory for clinical decision-making. For example, for the metastatic EGFR-mutated NSCLC, the National Comprehensive Cancer Network guideline recommended the EGFR-TKIs as their first-line therapy, 15 among them, this nomogram can help to recognize the high-risk subgroups that may need more intensive treatments like chemotherapy at the same time. In addition, for the high-risk subgroup among the whole population determined by our nomogram, we should pay closer attention and shorten the follow-up period in order to adjust treatment methods in a timely manner according to the changes of their tumor condition. We can also give them more palliative care like psychological or sentimental support and encourage them to participate in clinical trials of anticancer drugs. Furthermore, these tools may help the designers of clinical trials to get more equivalent baselines between different study groups. It is also worth noting that the SEER database covers 34.6% of the US population, 12 which, therefore, guarantees the representativeness of our nomogram and implies the potential universal application of our nomogram, which has an acceptable discrimination ability and excellent prediction accuracy. Notably, we did not include the NSCLC patients with stage M1a. It is because the prognosis of M1a patients is significantly better than M1b patients, and the presence with M1a disease would have a contradictory impact on M1a and M1b patients, which would result in wrong scores in M1a item of the nomogram.
Marital status, sex, race, age, histology, T stage, N stage, histological differentiation, the presence of bone metastasis, brain metastasis, liver metastasis, M1a disease, surgery of primary cancer, and chemotherapy were identified as the prognostic factors of the OS, which was in line with the previous studies. 5, 7, 8, 11, [16] [17] [18] Among them, surgery of primary cancer could notably improve the prognosis. Thus, we analyzed the characteristics of these patients who underwent surgery and found that all of them received radiation therapy, and most of them received chemotherapy. Surgery to the 
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Deng et al primary cancer site was treated as a part of the multimodality regimens. David et al queried the California Cancer Registry and identified 34,016 patients to make an unmatched survival analysis; they also found that the stage IV NSCLC patients who underwent surgical procedures as a part of their multimodality therapy had significantly longer median OS than these receiving non-surgical treatments (9.4-28 vs 2-10 months). 19 Given the patients' favorable responses to systemic therapies like targeted therapy and immunotherapy, surgery to the primary cancer might be reconsidered as a part of multimodality therapy. Surgery can provide enough tissue to enable detailed molecular and genetic subtyping of NSCLC. 20 It can also decrease patients' tumor burden and alleviate or eliminate the complications caused by tumors to improve patients' life quality. However, it should be noted that not all patients can benefit from surgery; whether surgical treatment should be performed on metastatic NSCLC patients should take various individual, treatment-related and disease-related factors into consideration and carefully discussed in a multidisciplinary setting. 21 Moreover, surprisingly, radiation therapy did not remain significant statistically in the multivariable analysis (P=0.143), which indicates that radiotherapy has a modest impact on OS, just as a previous study reported. 22 But radiation therapy is still an option of palliative care to relieve pain or complications of patients and may have potential to prolong patients' OS. AD was associated with the best prognosis, which might be partly interpreted by the fact that AD presents with much more EGFR gene mutations, making AD more sensitive to EGFR-TKIs. Among distant metastatic sites, liver metastasis was associated with the poorest prognosis, followed by bone metastasis, that was in high concordance with a previous research, which analyzed 17,431 lung cancer patients in Sweden. 7 In a word, our nomogram included rational prognostic factors of distantly metastatic NSCLC patients.
Limitations: 1) The important prognostic factors of advanced lung cancer that were identified in previous studies, such as performance status score, body mass index, smoking status, appetite condition, genotype characteristics, serum markers, skin/adrenal metastasis, the usage of EGFR-TKIs or vascular endothelial growth factor-targeted drugs, and the detailed information of chemotherapy were not taken into consideration in this study because there were no such information provided by the SEER database.
2,3,6,23 2) All patients were staged according to the seventh edition of the TNM classification for lung cancer; however, the coding rules on tumor extension made us difficult to restage the patients according to the latest eighth edition of the TNM classification. For example, CS extension code 600 included lung cancers extended to diaphragm, chest wall, or Pancoast cancer. Lung cancers extended to chest wall, Pancoast cancer, which are at stage T3 according to the seventh and eighth edition of the TNM classification while lung cancers extended to diaphragm is already changed to stage T4 according to the latest eighth edition of the TNM classification. 13, 24 As a result, we cannot determine the T stage of a patient with this code in the latest eighth edition of the TNM classification, which may result in inconvenience in the use of the nomogram.
3) The third limitation is the retrospective nature of the data collection from the SEER database. Moreover, overall sensitivity was 68% and 80% for chemotherapy and radiotherapy, respectively, despite a high specificity of these data. 25 4) The nomogram is only generalized based on the data of the patients in the USA and thus, might not be representative of the patients worldwide. 5) The SEER database only provided information on metastasis to bone, brain, and liver at diagnosis, without taking the metastasis during follow-up periods into consideration. Therefore, global prospective data with the latest TNM classification and more comprehensive prognostic factors are needed to improve this model.
Conclusion
A nomogram was established and validated to predict individual prognosis for the general distantly metastatic NSCLC patients. Global prospective data with the latest TNM classification and more comprehensive prognostic factors are needed to improve this nomogram. 
